Management of COVID-19 in people with epilepsy: drug considerations

People with epilepsy (PWE) are neither more likely to be infected by the coronavirus nor are they more likely to have severe COVID-19 manifestations because they suffer from epilepsy. However, management of COVID-19 in PWE may be more complicated than that in other individuals. Drug-drug interaction...

Descripción completa

Detalles Bibliográficos
Autores principales: Asadi-Pooya, Ali A., Attar, Armin, Moghadami, Mohsen, Karimzadeh, Iman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320844/
https://www.ncbi.nlm.nih.gov/pubmed/32594268
http://dx.doi.org/10.1007/s10072-020-04549-5
_version_ 1783551328250757120
author Asadi-Pooya, Ali A.
Attar, Armin
Moghadami, Mohsen
Karimzadeh, Iman
author_facet Asadi-Pooya, Ali A.
Attar, Armin
Moghadami, Mohsen
Karimzadeh, Iman
author_sort Asadi-Pooya, Ali A.
collection PubMed
description People with epilepsy (PWE) are neither more likely to be infected by the coronavirus nor are they more likely to have severe COVID-19 manifestations because they suffer from epilepsy. However, management of COVID-19 in PWE may be more complicated than that in other individuals. Drug-drug interactions could pose significant challenges and cardiac, hepatic, or renal problems, which may happen in patients with severe COVID-19, may require adjustment to antiepileptic drugs (AEDs). In this review, we first summarize the potential drug-drug interactions between AEDs and drugs currently used in the management of COVID-19. We then summarize other challenging issues that may happen in PWE, who have COVID-19 and are receiving treatment.
format Online
Article
Text
id pubmed-7320844
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-73208442020-06-29 Management of COVID-19 in people with epilepsy: drug considerations Asadi-Pooya, Ali A. Attar, Armin Moghadami, Mohsen Karimzadeh, Iman Neurol Sci Covid-19 People with epilepsy (PWE) are neither more likely to be infected by the coronavirus nor are they more likely to have severe COVID-19 manifestations because they suffer from epilepsy. However, management of COVID-19 in PWE may be more complicated than that in other individuals. Drug-drug interactions could pose significant challenges and cardiac, hepatic, or renal problems, which may happen in patients with severe COVID-19, may require adjustment to antiepileptic drugs (AEDs). In this review, we first summarize the potential drug-drug interactions between AEDs and drugs currently used in the management of COVID-19. We then summarize other challenging issues that may happen in PWE, who have COVID-19 and are receiving treatment. Springer International Publishing 2020-06-27 2020 /pmc/articles/PMC7320844/ /pubmed/32594268 http://dx.doi.org/10.1007/s10072-020-04549-5 Text en © Fondazione Società Italiana di Neurologia 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Covid-19
Asadi-Pooya, Ali A.
Attar, Armin
Moghadami, Mohsen
Karimzadeh, Iman
Management of COVID-19 in people with epilepsy: drug considerations
title Management of COVID-19 in people with epilepsy: drug considerations
title_full Management of COVID-19 in people with epilepsy: drug considerations
title_fullStr Management of COVID-19 in people with epilepsy: drug considerations
title_full_unstemmed Management of COVID-19 in people with epilepsy: drug considerations
title_short Management of COVID-19 in people with epilepsy: drug considerations
title_sort management of covid-19 in people with epilepsy: drug considerations
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320844/
https://www.ncbi.nlm.nih.gov/pubmed/32594268
http://dx.doi.org/10.1007/s10072-020-04549-5
work_keys_str_mv AT asadipooyaalia managementofcovid19inpeoplewithepilepsydrugconsiderations
AT attararmin managementofcovid19inpeoplewithepilepsydrugconsiderations
AT moghadamimohsen managementofcovid19inpeoplewithepilepsydrugconsiderations
AT karimzadehiman managementofcovid19inpeoplewithepilepsydrugconsiderations

Ejemplares similares